Open Label Phase 3 study of Solanezumab in Alzheimer’s Disease

• Research type

  Research Study

• Full title

  Protocol H8A-MC-LZAO Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid ß Antibody in Patients with Alzheimer’s Disease

• IRAS ID

  66298

• Sponsor organisation

  Eli Lilly and Company

• Eudract number

  2010-021155-11

• ISRCTN Number

  N/A

• Research summary

  Study LZAO is the extension study to the current LZAN study. It is a multicenter, open-label, Phase 3 study monitoring safety and long-term efficacy of solanezumab in patients with mild-to-moderate Alzheimer??s disease who have completed the current LZAN feeder Study. All patients in this extension study (including those who received active treatment and placebo in the LZAN study) will be administered solanezumab 400 mg once every 4 weeks.

• REC name

  London - South East Research Ethics Committee

• REC reference

  10/H1102/85

• Date of REC Opinion

  23 Jun 2011

• REC opinion

  Further Information Favourable Opinion